Bone health and HIV in resource-limited settings: a scoping review

Flavia Kiweewa Matovu, Lalita Wattanachanya, Mags Beksinska, John M. Pettifor and Kiat Ruxrungtham

Purpose of review
Sub-Saharan Africa and other resource-limited settings (RLS) bear the greatest burden of the HIV epidemic globally. Advantageously, the expanding access to antiretroviral therapy (ART) has resulted in increased survival of HIV individuals in the last 2 decades. Data from resource rich settings provide evidence of increased risk of comorbid conditions such as osteoporosis and fragility fractures among HIV-infected populations. We provide the first review of published and presented data synthesizing the current state of knowledge on bone health and HIV in RLS.

Recent findings
With few exceptions, we found a high prevalence of low bone mineral density (BMD) and hypovitaminosis D among HIV-infected populations in both RLS and resource rich settings. Although most recognized risk factors for bone loss are similar across settings, in certain RLS there is a high prevalence of both non-HIV-specific risk factors and HIV-specific risk factors, including advanced HIV disease and widespread use of ART, including tenofovir disoproxil fumarate, a non-BMD sparing ART. Of great concern, we neither found published data on the effect of tenofovir disoproxil fumarate initiation on BMD, nor any data on incidence and prevalence of fractures among HIV-infected populations in RLS.

Summary
To date, the prevalence and squeal of metabolic bone diseases in RLS are poorly described. This review highlights important gaps in our knowledge about HIV-associated bone health comorbidities in RLS. This creates an urgent need for targeted research that can inform HIV care and management guidelines in RLS.

Video abstract:
http://links.lww.com/COHA/A9.

Keywords
antiretroviral therapy, bone mineral density, HIV, resource-limited settings, tenofovir, vitamin D

INTRODUCTION
Resource-limited settings (RLS) that constitute low- and middle-income countries [1] continue to bear the greatest burden of the HIV epidemic globally [2]. Advantageously, the expanding access to highly active antiretroviral therapy has resulted in...
KEY POINTS

- Low BMD is generally higher among HIV-infected individuals in RLS compared with RRS, regardless of ART use.
- There are very limited published data in any RLS regarding longitudinal changes in BMD in HIV-infected persons, very minimal data on the effect of TDF-based ART on BMD regardless of study design, no longitudinal data on the effect of ART initiation on BMD among ART-naïve cohorts, and no data at all on fractures among HIV-infected individuals in RLS.
- There are high but similar prevalence of low vitamin D among HIV-infected individuals regardless of ART use in both RLS and RRS.
- There are no data on BMD and fracture risk in key populations of HIV-infected women on DMPA for contraception both in RLS and RRS, and no data in HIV-infected adolescents in RLS.
- Unlike RRS where medications such as EFV are no longer preferred, and alternatives to TDF with less bone toxicity are likely to be more frequently used, there are currently no strategies in RLS for minimizing bone loss among HIV-infected individuals which poses an urgent need for research that can inform management guidelines in metabolic bone complications in RLS.

Bone health and HIV in resource-limited settings

Dramatically increased survival of HIV-infected individuals in the last 2 decades [3]. With more HIV-infected individuals living longer, it is expected that medical comorbidities such as osteoporosis and fragility fractures will increase. Data from developed countries estimate that up to two-thirds of HIV-infected antiretroviral therapy (ART)-treated and ART-naïve individuals exhibit osteopenia or osteoporosis at the time of low bone mineral density (BMD) diagnosis, with those on ART at increased risk [4]. Importantly, studies in resource rich settings (RRS) are reporting increased evidence of fracture rates in the HIV-infected population, with fracture rates 30–70% higher than those among matched uninfected controls [5,6*,7*,8,9]. Fracture fragility are associated with significant loss of physical function, independence, and quality of life [10], as well as an increased risk of short-term and long-term mortality [11–13]. These data call for more strategic clinical management of HIV individuals that includes prevention or minimization of long-term metabolic complications of HIV infection and its treatment in addition to treating opportunistic infections. In this review, we summarize recently published and presented studies that inform the discussion on bone health among HIV-infected persons in RLS. We highlight the epidemiology of HIV and bone loss in RLS, and among special populations, including HIV-infected young women and perinatally infected adolescents. We focus on three main areas of interest in HIV metabolic bone disease in RLS: effects of HIV and ART, vitamin D insufficiency and other risk factors for bone loss, and fracture risk assessment. We further identify important gaps in research and clinical management as well as make recommendations for future research priorities that would help address these HIV-related, bone health comorbidities in RLS.

Bone mass and HIV in resource-limited settings

The World Health Organization has categorized low BMD into osteopenia and osteoporosis. In postmenopausal women and men, 50 years and above, osteoporosis is defined as a T-score at or below 2.5 SD whereas osteopenia is defined as a T-score between 1 and 2.5 SD below the young adult mean value. Premenopausal women, men below 50 years or children who have a BMD Z-score at or below 2.0 of the age and sex-matched population are classified as having low bone mass. [14]. In the general population, a decline in BMD, assessed by dual-energy X-ray absorptiometry (DXA), is associated with an increased risk of subsequent fractures [15]. Data from RRS consistently show that HIV infection is associated with low BMD and increased fracture risk [5,6*,7*,8,9]. A meta-analytic review of 11 studies by Brown et al. involving 884 HIV-infected individuals and 654 controls estimated the prevalence of low BMD among HIV-infected individuals to be as high as 67%, 15% of whom had osteoporosis. The magnitude of low BMD was 6.4 times greater and that of osteoporosis 3.7 times greater than in HIV-uninfected controls [4]. Further, in a recent meta-analysis, fracture risk was 1.35-fold higher in HIV-positive compared to HIV-negative controls [7*]. Although underlying mechanisms leading to reduced BMD in HIV-infected persons are still unclear, they are believed to be multifactorial and include both traditional and HIV-specific risk factors [4,16–25]. Owing to physiological, psychological, and lifestyle factors, HIV-infected persons are likely to have many of the traditional risk factors for low BMD such as physical inactivity, low body weight, nutritional deficiencies (including inadequate calcium and vitamin D intake), depression, smoking, heavy alcohol use, oligo-/amenorrhoea, and hypogonadism [26–35]. Among the nontraditional causes, a direct effect of HIV and its treatment have been most often quoted; chronic inflammation induced by HIV may impact bone metabolism [36–39]. In addition, ART significantly contributes
Bone complications in HIV

to bone loss among HIV-infected persons [40]. Among individuals on ART, studies in RRS consistently report a 2–6% decline in BMD over the first few years after treatment initiation [25,41], regardless of ART choice [26].

In RLS with a disproportionately high burden of HIV and background nutritional deficiencies [42], known risk factors for low BMD remain similar to those in RRS [25,43,44]. However, some of these risk factors such as low BMI, malnutrition, advanced disease, longer duration since HIV diagnosis and higher HIV viral load are more common in HIV-infected populations in RLS [45*,46,47*,48]. These risk factors coupled with more widespread use of non-BMD sparing ART-like tenofovir disoproxil fumarate (TDF) and efavirenz (EFV) make the extremely high prevalence of low BMD in some RLS almost inevitable. Unfortunately, data on BMD among HIV-infected individuals are currently scanty and subject to methodological concerns such as cross-sectional design, lack of appropriate control groups, and local BMD reference data. The majority of the studies did not use local noninfected controls for comparison; the United States National Health and Nutrition Examination Survey reference data being used instead and comparisons were not adjusted for differences in body composition and size. Our review revealed overlapping prevalence of low BMD in RLS and RRS, with a generally higher prevalence of low BMD in RLS overall compared to RRS (Table 1 and Fig. 1). Data from both low-income countries such as Uganda [45*], Nigeria [47*], India [46], Indonesia [48] and middle-income countries (South Africa [49], Brazil [27], Turkey [50], China [51,52], Israel [53], and Thailand [54]) as well as mixed settings (South Africa, India, Thailand, Malaysia, and Argentina [55]) show varying levels of low BMD with some studies reporting a high prevalence of low BMD in HIV-positive individuals of up to 85% [53]. However, a few authors such as Hamill et al. [49] from South Africa have reported comparable BMD levels between HIV-infected women and appropriate uninfected controls regardless of disease severity. The high BMI of participants in this study may have had a sparing effect on bone loss. In contrast, a study comparing ART-naive to ART-experienced patients on long-term suppressive ART in western India found extremely high prevalence of low BMD, 80.4% among ART-experienced, and 67% among ART-naive patients, but no local uninfected controls were used [46]. Another cross-sectional study among young HIV-infected Israeli women of Ethiopian and Caucasian origin found a higher prevalence of low BMD, 85% among Ethiopians compared to 40% seen in the Caucasians [53] which the authors attributed to poorer vitamin D status among Ethiopian women [53]. Similar proportions of low BMD have been reported by recently published data from RRS [56*,57–60] with the exception of a few studies [61–63].

There are very limited data in any RLS regarding BMD longitudinal changes among HIV-infected persons. In a 48-week, multisite, second-line trial in South Africa, India, Thailand, Malaysia, and Argentina [55], HIV-infected patients who initiated a second-line regimen experienced additional bone loss. We did not find any longitudinal data on the effect of ART initiation on BMD among ART-naive cohorts, or any data on fractures among HIV-infected individuals in RLS.

Role of tenofovir

A strong body of evidence from longitudinal data in RRS shows that among the different antiretroviral drugs, the potential effect of TDF on bone health is particularly concerning [64–70]. In ART-naive HIV-positive individuals, initiating TDF-containing ART was associated with greater bone loss over the first few years compared to TDF-sparing regimens [67,69–71]. With ART-initiation, there is a rapid acceleration of bone turnover; bone resorption outstrips bone formation, likely accounting for the decrease in BMD [72,73]. Consistent with these findings, Brown and others [66,67,74] have shown that ART initiation is associated with a 2–6% loss of BMD over the first 48–96 weeks of therapy that does not return to baseline after prolonged HIV RNA suppression and also reoccurs after reinitiation of ART after treatment failure. In another adult study comparing TDF-containing and noncontaining regimens, Gallant et al. [64] observed increased bone resorption and loss in the TDF-containing arm compared to patients receiving an alternate NRTI ( stavudine), at both the LS (−3.3 vs. −2.0%) and hip (−3.2 vs. −1.8%). Importantly, the majority of BMD loss was observed within the first 24–48 weeks of treatment, and thereafter, BMD loss slowed, but BMD did not recover over the 144 weeks of the study. Similarly, a study comparing TDF to abacavir an NRTI revealed a greater loss of BMD at total hip (−3.6 vs. −1.9%) and LS (−2.4 vs. −1.6%) in the TDF group. Again, BMD loss occurred closer to initiation of therapy and was maximal in the spine at 24 weeks and in the hip at 48 weeks [66]. More interestingly, switching from a TDF-containing regimen to an alternative NRTI leads to an increase in BMD [71]. Though the mechanism through which TDF reduces bone mass is not clear, there is more evidence suggesting that TDF induces renal dysfunction [75–87]. TDF has been shown to induce proximal renal tubular
| Country (region) | Reference | Type of study | Patients | % Women | Age, mean or median (SD or IQR) | Prevalence of Low BMD | Osteopenia | Osteoporosis | Key findings or Remarks (DXA machine) |
|-----------------|-----------|---------------|----------|---------|-------------------------------|----------------------|-------------|-------------|---------------------------------------|
| Low–middle-income countries (LMICs) | | | | | | | | | |
| Uganda (SSA) | Wandera et al., 21st CROI [EARNEST trial] [45] | Cross-sectional analysis of prospective study, 2010–2014 | 181 HIV-infected patients failing their first line ART (duration of first line ART 3.7 [(2.7–5) years], 16.7% had used TDF, CD4 67 cells/ml (35–151)) | 69 (12.8% postmenopausal) | 35 (31, 41) LS 50.9%, TH 24.8% | LS 35.3%, TH 23.7% | LS 8%, TH 1.1% | Low BMD at LS was associated with both low BMI and use of TDF in first-line regimen. At TH, a low BMI was predictive of low BMD. (Discovery Hologic.) |
| India (SA) | Dravid et al. [46] | Cross-sectional study, June to December 2013 | 536 patients: 496 HIV-infected patients on ART 40 HIV-infected ART-naive patients | 34 | 42 | LS or TH 80.4% | LS or TH 51% | LS or TH 29.4% | Age, low BMI, current smoking, and menopause were associated with low BMD. Choice of ART use (TDF vs. non-TDF, PI vs. no PI) did not influence loss of BMD. (Lunar Prodigy.) |
| Nigeria (SSA) | Alonge et al. [47] | Cross-sectional study, September to December 2010 | 1005 HIV-positive patients (78.1% on ART; PI 12.6%), median CD4 371 cells/ml, median VL 200 copies/ml | 72 | 41.3 ± 10 | n/a | Lt. distal radius 46.6% | Lt. distal radius 31.9% | Osteoporosis was higher in those aged >40 years, women, single, and underweight. There was no difference in BMD of those with or without PI containing medications and treatment-naive patients. (Specific DXA machine was not indicated.) |
| Indonesia (EA/P) | Massenyi et al. [48] | Cross-sectional study, January to June 2012 | 73 HIV-positive ART-naive patients (mean CD4 144.7 cells/μl and mean VL 272.3 copies/ml | 32.9 | 33.1 ± 8.3 | LS or FN 43.8% | LS or FN 35.6% | LS or FN 8.2% | Low BMD was correlated with HIV stage (r = 0.337, P < 0.001) (Lunar DPX.) |
| South Africa (SSA) | Hamill et al. [49] | Cross-sectional study, February 2010 to July 2010 | 75 HIV-infected ART-naive patients with low CD4 counts (200 cells/μl) 74 HIV-positive ART-naive patients with relatively preserved CD4 cell counts (>350 cells/μl) 98 healthy controls | 100 | 33.4 ± 6.5 | No significant differences in BMD at LS, TH, or FN. Proportions with osteopenia or osteoporosis were not reported. | HIV-positive women did not have lower BMD compared to HIV-negative controls despite the pre-ARV group being lighter with lower BMI. (Hologic QDR 4500A.) |

(Continued)
| Country (region) | Reference | Type of study | Patients | % Women | Age, mean or median (SD or IQR) | Prevalence of | Key findings or Remarks (DXA machine) |
|-----------------|-----------|---------------|----------|---------|-------------------------------|---------------|--------------------------------------|
| Turkey (EU/CA)  | Aydin et al. [50] | Cross-sectional study, June 2010 to May 2011 | 126 HIV-infected patients [63.5% on ART, either AZT/3TC or TDF/FTC, LPV/r or EFV], mean CD4 313.8 cells/μl | 16 | 40.1 ± 11.3 | LS or TH 77.7% | LS or TH 53.9% | LS or TH 23.8% | Neither NNRTI nor PI containing regimens was associated with low BMD. High VL, using and duration of ART were associated with bone loss. (Norland) |
| China (EA/P)    | Zhang et al. [51] | Prospective study, April 2007 to March 2011 | 40 HIV-infected ART-naïve patients 40 healthy controls | 12.5 | 37.3 ± 9.9 | LS or TH 80% | LS or TH 40% | LS or TH 40% | At baseline, LS BMD of HIV-infected patients was lower than controls (1.195 ± 0.139) vs (1.138 ±0.112). Proportions with osteopenia or osteoporosis were not reported. |
| China (EA/P)    | Wang et al. [52] | Cross-sectional study, January 2010 to May 2014 | 21 ART-naïve patients with acute HIV infection [mean CD4 420 ± 152 cells/μl, MSM 95.2%] 55 ART-naïve patients with chronic HIV infection [mean CD4 286 ± 168 cells/μl, MSM 81.7%] 71 healthy controls | 0 | 31.1 ± 6.9 | LS or TH 33.3% | LS or TH 33.3% | LS or TH 0% | With ART initiation, LS, FN, and TH BMD reduced significantly in HIV-infected patients (annual percentage decline 1.78–3.28%). (Lunar Prodigy Advance PA + 300388.) |
| Israel (ME/NA)  | Shahar et al. [53] | Cross-sectional study, Summer 2009 | 43 HIV-infected Ethiopians [mean CD4 233 cells/μl, 82% on ART, 20 study participants on PI] 32 HIV-infected Caucasians [mean CD4 264 cells/μl, 64% on ART, 21 study participants on PI] | 100 | 35.9 ± 8.2 | LS 85%, TH 55%, n/a | FN 65% | n/a | Low BMD in HIV-infected patients was associated with duration of HIV infection and ART use. (Lexxos, France) |
| Country         | Authors | Study Design | Sample Size | Median Age | Male/Female | Mean CD4 (cells/µl) | BMD Loss | NRTI Use | Other Treatments |
|----------------|---------|--------------|-------------|------------|-------------|---------------------|----------|----------|-----------------|
| Thailand (EA/P) | Wattanachanya et al. [54] | Cross-sectional analysis of prospective study, 2010–2011 | 220 HIV-positive ART-naïve patients | 46.8 | Male 39 ± 6, female 39 ± 4 | n/a | LS, TH or FN | 20.9% (men), 23% (women) |
|                |         |              |             |            |             |                     |          |          | 2.3% (men)      |
| South Africa, India, Thailand, Malaysia, Argentina | Martin et al. [12], Haskelberget et al. [55] | Prospective study, 2010–2011 | 210 HIV-infected patients failing their first line ART with current CD4 202 (104–307) cells/µl; median duration of ART use 3.4 years, AZT 34%, d4T 48%, TDF 17% at baseline | 52 | Male 40 ± 6, female 41 ± 5 | n/a | LS 31.3%, TH 19.7% (at baseline) | 0% (men), 2.3% (women) |
|                |         |              |             |            |             |                     |          |          | 0.7% (men), 0.8% (women) |
| USA1 (NA)      | Battalora et al. [HOPS and SUN study] [56] | Cross-sectional analysis of prospective study, 2004–2012 | 1006 HIV-infected patients with median CD4 461 cells/µl (96.6% on ART, 67% non-Hispanic White) | 17 |  | 43 (36, 49) | FN 40% | FN 36% | FN 4% |
|                 |         |              |             |            |             |                     |          |          | During 4,068 person-years of observation, 85 incident fractures occurred, predominantly rib/sternum, hand, foot, and wrist. Osteoporosis and current/prior tobacco use were associated with incident fracture. (Lunar or Hologic, reference standard: NHANES III database.) |
| UK* (EU/CA)    | Short et al. [57] | Cross-sectional study, May to August 2008 | 168 HIV-infected patients (63% on ART; PI 27%, NRTI 45%, NRTI included TDF 47%) | 0 |  | 45 (38, 51) | n/a | LS, TH, or FN 58% | LS, TH, or FN 12% |
|                |         |              |             |            |             |                     |          |          | Number of fractures since HIV diagnosis was increased among those with osteoporosis. Duration of infection >13 years was associated with osteoporosis. (Lunar or Hologic, reference standard: NHANES III database.) |

(Continued)
Table 1 (Continued)

| Country (region) | Reference | Type of study | Patients | % Women | Age, mean or median (SD or IQR) | Prevalence of Low BMD | Prevalence of Osteopenia | Prevalence of Osteoporosis | Key findings or Remarks (DXA machine) |
|------------------|-----------|---------------|----------|---------|-------------------------------|----------------------|------------------------|--------------------------|----------------------------------|
| Italy (EU/CA)    | Mazzotta et al. [58] | Cross-sectional study, April 2009 to March 2011 | 163 HIV-infected patients (79.7% on ART; PIs 59.2%, TDF 70%) | 29.4 | 44.2 ± 10 | LS or TH; 63.2% | LS or TH; 49.7% | LS or TH; 13.5%; LS or TH 19.6% (Z-score ≤ -2) | Low BMD was associated with lower BMI, AIDS diagnosis, HCV co-infection, ART, and nontraumatic fractures (NTBFs). Prevalence of NTBFs was 27.0%, predictors; male sex, HCV co-infection, lower FN Z-scores. (Hologic QDR 4500A.) |
| The Netherlands (EU/CA) | Kooij et al. [59] | Cross-sectional study, 2010–2012 | 581 HIV-positive patients (94.7% on ART; NRTI/TDF 96.4/77.1%, PI 43.6%, NNRTI/NVP 60.4/30.2%) | 11.5 | 52.7 (48.3, 59.4) | n/a | LS 34%, FN 43%, TH 29% | LS 11%, FN 4%, TH 2% | Low BW was negatively associated with BMD in HIV-positive persons. Regardless of HIV status, younger MSM had lower BMD than older MSM, heterosexual men, and women. (Hologic QDR 4500W, the reference standard: NHANES database.) |
| Japan (EA/P)     | Kinai et al. [60] | Cross-sectional study, February 2012 to June 2013 | 184 HIV-infected men (93% on ART; PIs 64%, TDF 62%), median CD4 493 cells/μl | 0 | 43 (38, 51) | n/a | LS 46% FN 54% | LS 10% FN 12% | Low BMD was associated with long-term treatment with a PI and a low BMI. Patients who discontinued PI had a higher BMD than those who currently use PI at LS but not at FN. (Hologic QDR 4500W.) |
| USA2b (NA)       | Overton et al. [61] | Cross-sectional analysis of prospective study, September 2011 to February 2012 | 165 HIV-infected patients on EFV/FTC/ TDF regimen (33% non-Hispanic Black; median CD4 341 cells/μl) Pre vitamin D/Calcium group (n = 79) Placebo group (n = 86) | 9.7 | At baseline | LS 9%; TH 5% | n/a | n/a | Authors evaluated vitamin D3 (4000 IU daily) plus calcium (1000 mg calcium carbonate daily) supplementation on bone loss associated with ART initiation. BMD loss in the first year after ART initiation may be minimized by calcium and vitamin D supplementation. (Specific DXA machine was not indicated.) |
### USA3 (NA)

**Cotter et al.** [62]

Cross-sectional analysis of prospective study
February 2011 to July 2012

210 HIV-positive patients (40% African) 41 39 (33, 46)

At baseline; LS 24.3%; TH 13.8%; FN 23.8%

264 HIV-negative controls (25% African) 56 42 (34, 49)

LS 12.5%; TH 5.7%; FN 11.7%

HIV was independently associated with lower BMD at femoral neck, total hip and lumbar spine. Lunar Prodigy DXA (GE Medical Systems, Madison, Wisconsin, USA.)

### Mixed LMICs and HICs

**Carr et al.** (STARTBone Mineral Density Substudy) [63]

Cross-sectional analysis of prospective study, June 2011 to June 2013

424 ART-naïve participants with mean CD4 688 ± 152 cells/µl

34 ± 0.1

LS, TH or FN 35.1%, FN 18.8%

n/a

LS, TH or FN 1.9%, FN 0.5%

Lower BMD was associated with female sex, Latin/Hispanic ethnicity, lower BMI and higher estimated GFR. Longer time since HIV diagnosis was associated with lower TH BMD, but not with CD4 cell count or viral load. [Lunar or Hologic, reference standard: NHANES III database (hip) and Hologic’s reference data (spine).]

Data shown in the table include published articles and abstracts related to prevalence of low BMD in HIV-infected adolescents or adults from RLS in 2014 and 2015 plus articles of special interest from 2013. However, for RRS, only the articles published in mid-2014 to 2015 and had more than 100 HIV-infected participants were included. BMD, bone mineral density; FN, femoral neck; HICs, high-income countries; LMICs, low–middle-income countries; LS, lumbar spine; n/a, not available; TH, total hip; VL, viral load.

- **a** In this study, low BMD was defined as Z-score < -2 at LS or TH.
- **b** In this study, osteopenia and osteoporosis were defined as T- or Z-score < -1 and T- or Z-score < -2.5, respectively.
- **c** In this study, low BMD was defined as T-score < -1 in those older than 40 years or Z < 2.0 in those younger than 40 years, respectively.
dysfunction that results in excessive glomerular filtration, renal tubular acidosis phosphate loss [83] and possible impairment in vitamin D hydroxylation [75,76,80,86–94].

In RLS, the two WHO recommended first line ART treatment regimens for adults and children above 15 years contain TDF; TDF, lamivudine (3TC) and EFV or TDF, emtricitabine (FTC), and EFV, which exposes many HIV-infected individuals to the negative impact of TDF on bone health [3,95]. Conversely, there are scarce data on the effect of TDF-based ART on BMD in these settings. Martin et al. [55] reported that HIV-infected patients who initiated a second-line regimen had a greater bone loss if they were on TDF for longer duration during the 48 weeks of the study. For every 1 year of TDF use, the femur BMD reduced by 1.58% and spine BMD by 1.65% (P < 0.001).

Vitamin D and bone health in HIV

Worldwide, it’s estimated that more than one billion people are characterized as having vitamin D deficiency (<20ng/ml), or insufficiency (<30ng/ml) regardless of the economic setting. According to a recent review by Mansueto et al. [96] the prevalence of vitamin D deficiency among HIV-infected individuals in both RLS and RRS varies widely across studies ranging from 25 to 93%, with an overall prevalence of 70.3 to 83.7%. Similarly, our review yielded high but similar prevalence of low vitamin D among HIV individuals regardless of ART use in both RLS [50,53,97–102] and RRS [61,103–109] with insufficient levels of up to 90% in Turkey [50] and the USA [103], Belgium [108], Spain [109] (Table 2 and Fig. 2). The authors ascribed the high prevalence of vitamin D deficiency seen among Turkish [50], and Israeli [53] to skin coverage with resultant reduced sunlight exposure. Among individuals on ART, several cross-sectional studies from both RRS and RLS have shown an association between EFV use and low 25-hydroxyvitamin D (25(OH)D) [30,97,104,110–113]. NNRTIs, especially EFV which are widely used to treat HIV infection in RLS are hypothesized to enhance 25(OH)D catabolism through the induction of cytochrome P450 enzymes (CYP24A) [112] which reduce 25(OH)D concentrations. Among HIV-infected individuals, vitamin D insufficiency has been associated with a higher risk of HIV disease progression, death and virologic failure after ART [96,114]. In addition, vitamin D deficiency has been reported to independently increase the risk of low BMD [115]. In view of this, supplementation with vitamin D has been reported to mitigate bone loss [61,105]. In a recent randomized trial Overton et al. [61] found that BMD loss in the first year after ART initiation may be minimized by calcium and vitamin D supplementation. By way of contrast, none of the studies we reviewed supported an association between vitamin D insufficiency and low BMD [61]. Though a cross-sectional study by Shahar et al. [53] among HIV-infected Israeli women of Ethiopian and Caucasian origin reported lower levels of BMD among vitamin D deficient individuals, these findings were limited by the small sample size in addition to lack of an HIV-uninfected control group. Larger studies with a suitable comparison of HIV-uninfected controls are
### Table 2. Prevalence of low vitamin D in HIV-infected individuals in low- to middle-income countries versus high-income countries

| Country (region) | Reference | Type of study | Patients | % Women | Age (mean or median; SD, IQR) | Results | Remarks |
|------------------|-----------|---------------|----------|---------|-----------------------------|---------|---------|
| Turkey (EU/CA)   | Aydin et al. [50] | Cross-sectional study, June to October 2010 | 96 HIV-infected patients (80.2% on ART) | 18 | 40.1 (range, 20–70) | Patients on ART: 14.3% had 25(OH)D < 10 ng/ml, 67.5% had 25(OH)D 10–20 ng/ml; patients without ART: 15.8% had 25(OH)D < 10 ng/ml, 73.7% had 25(OH)D 10–20 ng/ml | 25(OH)D levels were low in women with veiled dressing style. No relation between low BMD and 25(OH)D levels. |
| Israel (ME/NA)   | Shahar et al. [53] | Cross-sectional study, Summer 2009 | 43 HIV-infected Ethiopians [mean CD4 233 cells/µl, 82% on ART, 20 study participants on PI] & 32 HIV-infected Caucasians [mean CD4 264 cells/µl, 64% on ART, 21 study participants on PI] | 100 | 35.9 ± 8.2 | 65% had 25(OH)D < 10 ng/ml, 16.6% had 25(OH)D 10–20 ng/ml | PIs used were LPV/r, invirase/r, IDV. All participants were living in Israel for at least 10 years. Significantly more Ethiopian than Caucasian women covered their face and hands. |
| Botswana (SSA)   | Steenhoff et al. [97] | Prospective study, December 2011 to April 2012 | 60 HIV-infected study participants (PI 25%, EFV 33%, NVP 42%, TDF/NNRTI 13%) | 50 | 19.5 ± 12 | At baseline: 5% had 25(OH)D < 20 ng/ml, 26.5% had 25(OH)D 20–31 ng/ml, Mean 25(OH)D was 36.5 ng/ml in 4000IU group and 34.5 ng/ml in 7000 IU group. At 12 weeks: 1.5% had 25(OH)D < 20 ng/ml, 16.8% had 25(OH)D 20–31 ng/ml. Mean 25(OH)D was 54.8 ng/ml in daily 4000 IU group and 56.5 ng/ml in daily 7000 IU group. | Δ25D was two-fold higher in study participants on EFV or NVP compared to those on PIs. At 6 weeks, both NNRTI regimens resulted in greater Δ25D than those on PIs. Study participants on EFV or NVP did not differ in Δ25D from study participants on other regimens. |
| Country (region) | Reference | Type of study | Patients | % Women | Age (mean or median; SD, IQR) | Results | Remarks |
|-----------------|-----------|---------------|----------|---------|------------------------------|---------|---------|
| Thailand1 (EA/P) | Chokephaibulkit et al. [98] | Cross-sectional study, October 2010 to February 2011 | 101 perinatally HIV-infected adolescents on ART (NNRTI-based: NVP 30%, EFV 20%, and PI-based: 50%), median CD4 646 cells/µL | 50 | 14.3 (13, 15.7) | Median 25(OH)D was 24.8 ng/ml, 24.7% had 25(OH)D < 20 ng/ml, 46.5% had 25(OH)D 20–30 ng/ml | No associations between vitamin D deficiency and BMI, BMD, EFV use, HIV RNA, CD4, or self-reported sunlight exposure were observed. |
| Thailand2 (EA/P) | Avihingsanon et al. [99] | Cross-sectional analysis of cohort, July 2010 to June 2011 | 673 HIV-infected adults (93% on ART; EFV 31%, TDF 79% and 57% of patients had previously used d4T), median CD4 571 cells/µL | 47 | 41.5 (37.2, 47) | 40.6% had 25(OH)D < 20 ng/ml, 29.9% had 25(OH)D 20–30 ng/ml | Female sex, age > 37 years, and EFV use were independent predictors of hypovitaminosis D. |
| Thailand3 (EA/P) | Aurpibul et al. [100] | Cross-sectional study, March to September 2011 | 80 perinatally HIV-infected children on ART (NVP-based 55%, EFV-based 31%, PI-based 14%), median CD4 784 cells/µL | 56 | 12.2 (9.1, 14.3) | Median 25(OH)D was 33.5 ng/ml, 10% had 25(OH)D < 20 ng/ml, 33% had 25(OH)D 21–29 ng/ml | Only geographic location was significantly associated with low vitamin D level. |
| Brazil 1 (LA) | Sales et al. [101] | Cross-sectional study, August 2011 to December 2013 | 32 HIV-infected women (most were on ART but type of ART was not indicated) | 100 | 41.7 | 15.63% had 25(OH)D < 10 ng/ml; 65.63% had 25(OH)D 11–29 ng/ml | Factors related to the virus itself and to the use of ART may have contributed for the low vitamin D levels. |
| Brazil 1 (LA) | Sales et al. [101] | Cross-sectional study, August 2011 to December 2013 | 66 HIV-infected men | 0 | 39 | 18.75% had 25(OH)D > 30 ng/ml; 12.12% had 25(OH)D < 10 ng/ml, 71.43% had 25(OH)D 11–29 ng/ml, 15.31% had 25(OH)D > 30 ng/ml | |
### Brazil 1 (LA)

**Canuto et al. [102]** Cross-sectional study, September 2013

- 125 HIV-infected patients (83.2% on ART but type of ART was not indicated)
- Mean 25(OH)D was 39.3 ng/ml, 1.6% had 25(OH)D < 20 ng/ml, 22.4% had 25(OH)D 21–29 ng/ml
- Higher 25(OH)D levels were associated with female sex, no use of sunscreen, and previous opportunistic infections.
- Lower values were associated with the use of ART, overweight and obesity.

### High-income countries

#### USA 1 (NA)

**Schwartz, Moore et al. [103]** Cross-sectional study, October 2009 to January 2010

- 507 HIV-negative study participants
- 358 HIV-positive ART naive patients
- 893 HIV-positive patients on ART (P 61%, NRTI 98%, NNRTI 26%)
- Median 25(OH)D was 14 ng/ml; 72% had 25(OH)D < 20 ng/ml; 18% had 25(OH)D 20–30 ng/ml; Median 25(OH)D was 14 ng/ml; 70% had 25(OH)D < 20 ng/ml; 20% had 25(OH)D 20–30 ng/ml; Median 25(OH)D was 17 ng/ml; 57% had 25(OH)D < 20 ng/ml; 24% had 25(OH)D 20–30 ng/ml
- Vitamin D levels were lower if ART included efavirenz (15 vs. 19 ng/ml, P < 0.001).

#### USA 2 (NA)

**Hidron et al. [104]** Cross-sectional study, 2007–2010

- 933 HIV-infected patients (82% on ART; TDF/EFV 31.6%, TDF without EFV 29.9%, no TDF 20.8%)
- 5355 HIV-negative study participants
- Median 25(OH)D was 19 ng/ml; 53.2% had 25(OH)D < 20 ng/ml
- Risk factors for vitamin D deficiency in HIV-positive patients included black race, winter season and higher GFR, increasing age and TDF use.

(Continued)
| Country (region) | Reference | Type of study | Patients | % Women | Age (mean or median; SD, IQR) | Results | Remarks |
|-----------------|-----------|---------------|----------|---------|-----------------------------|---------|---------|
| USA 3 (NA)      | Lake et al. [105] | Cross-sectional analysis of prospective study, June 2010 to April 2011 | 122 HIV-infected patients on ART (PI 34%, NNRTI 58%, raltegravir 17%, TDF 80%, ABC 29%), mean CD4 520 cells/µl | 5 | 49 [41, 55] | Median 25(OH)D was 20 ng/ml; 67.2% had 25(OH)D <30 ng/ml | After 12 weeks of vitamin D supplementation (vitamin D3 50000 IU twice weekly for 5 weeks, then 2000 IU daily), 81% of insufficient persons achieved 25OHD ≥30 ng/ml. 25OHD repletion rates were comparable between HIV-positive patients and controls. |
| Australia (EA/P) | Klassen et al. [106] | Cross-sectional study, January 2008 to December 2012 | 997 HIV-infected patients [66% on ART; EFV 24%, NNRTI ± PI 25%, no NNRTI/PI 17%] | 12 | 41 [32,48] | Mean 25(OH)D was 24.8 ng/ml; 40% had 25(OH)D <20 ng/ml; 71% had 25(OH)D <30 ng/ml | Men, Caucasian country of origin, summer/autumn, total cholesterol to HDL ratio >5.5 and HIV infection were associated with vitamin D deficiency. |
| Australia (EA/P) | Klassen et al. [106] | Cross-sectional study, May 2009 to April 2010 | 3653 HIV-uninfected individuals | 53 | 50 [39, 61] | Mean 25(OH)D was 27.6 ng/ml; 22% had 25(OH)D <20 ng/ml; 63% had 25(OH)D <30 ng/ml | |
| United Kingdom (EU/CA) | Gedela et al. [107] | Cross-sectional study, January 2008 to December 2009 | 253 HIV-infected ART-naive study participants (64.4% were white and 35.6% were black or other ethnicity) with median CD4 450 cells/µl | 18 | 36 [range, 16–75] | 12.6% had 25(OH)D ≤10 ng/ml; 58.5% had 25(OH)D ≤20 ng/ml | Vitamin D deficiency was common among ART naive patients, with those of nonwhite ethnicity at highest risk; no association was found with CD4 cell count, HIV viral load, and HIV clinical staging. |
| Country (EU/CA) | Authors et al. | Study Design, Dates | Study Population | Median 25(OH)D (range) | 25(OH)D <30 ng/ml associated with specific factors | 25(OH)D <10 ng/ml associated with specific factors |
|----------------|---------------|-------------------|----------------|------------------------|-----------------------------------------------|--------------------------------------------------|
| Belgium (EU/CA) | Theodorou et al. [108] | Retrospective study, December 2005 to March 2011 | 2044 HIV-infected study participants (73.4% on ART; EFV 15.8%, 2NRTI/NNRTI 23.2%, 2NRTI/PI 35.9%; second line 14.2%) | 41.5 (range, 20–85) | - | - |
| Spain (EU/CA) | Ballón et al. [109] | Prospective study, 2012 | 365 HIV-infected patients (98% on ART; TDF/FTC 77%, the remaining on ABC/3TC, EFV 33%) | 24 (range, 22–75) | - | - |

Median 25(OH)D was 13.8 ng/ml, 32.4% had 25(OH)D <10 ng/ml, 89.2% had 25(OH)D <30 ng/ml is associated with general factors (female sex, winter season) and specific factors related to HIV (duration of treatment, second line treatments with multiple and complex combinations of ART). 25(OH)D <10 ng/ml is associated with a low CD4 cell count, a higher CDC stage and EFV therapy.

Data shown in the table includes published articles and abstracts related to prevalence of hypovitaminosis D in HIV-infected adolescents or adults from RLS in 2014 and 2015 plus articles of special interest [1] from 2013. However, for RRS, only the articles published in mid-2014 to 2015 and had more than 100 HIV-infected participants were included. HICs, high-income countries; LMICs, low-to-middle-income countries; SSA, sub-Saharan Africa.
needed to quantify the association between vitamin D status and BMD or fracture risk in HIV populations in RLS, and whether vitamin D supplementation mitigates bone loss.

**Bone health among HIV-infected young adult women**

In RLS, the HIV burden among young adult women is high [2]. Women account for approximately 57% of the 34 million people living with HIV/AIDS. Most women living with HIV are of reproductive age [2], and the provision of reproductive health services is a crucial part of their HIV care. However, certain types of hormonal contraception have been associated with long-term metabolic dysregulation, particularly low BMD. In RLS with the highest unmet need for contraception, depot medroxyprogesterone acetate (DMPA) is the preferred contraceptive option across the different age groups [116] with approximately 15 million current users in the sub-Saharan African region alone [117]. Among HIV-infected women in particular, DMPA remains effective [118] because of its lack of interactions with antiretroviral drugs [119–121]. However, owing to its hypoestrogenic effects [122], DMPA has also been associated with reduced BMD [123–130]. The few published observational studies on the association between DMPA and fracture risk in RRS suggest increased risk of fractures among DMPA users [131,132]. For example, a large population-based control study by Meier et al. [131] showed a 50% increased risk of incident fractures among 20 to 44-year-old European DMPA users receiving 10 or more injections compared to nonhormonal users, among those who had received 10 or more injections. It must also be noted that all the above studies were conducted among HIV-negative individuals. Our review did not yield any published data on the effect of DMPA on BMD or fracture risk among HIV-infected women either in RRS or RLS. This presents a critical gap in policy and clinical management guidelines for HIV infected women.

**Bone health among HIV-infected adolescents**

With the scale up of ART, more HIV-infected children are surviving into adolescence. In 2012, an estimated 2.1 million adolescents (10–19 years) were living with HIV in RLS [2,133], constituting over 95% of all HIV infections in this age group [2]. Although global data on ART coverage for adolescents are not available, the WHO ‘Early Release Guideline’ recommending initiation of ART in all individuals living with HIV, regardless of CD4 cell count raises further the number of adolescents in need of treatment. Perinatally infected individuals have the greatest cumulative life-time exposure to HIV and its treatment which results in increased risk of associated comorbidities, including possible reduced bone mass at a critical time of peak bone mass (PBM) accrual. Data show that a lower PBM in the young is a major determinant of subsequent osteoporosis and fracture in older adults [134–137]. Several studies from RRS support an independent, dose–response relationship between BMD and...
risk of osteoporotic fractures [135,138–148]. For example, a 10% increase in PBM in young women is associated with an estimated 50% reduction in fracture risk after menopause [135]. Although there have been a few controversies among HIV individuals on ART [133,149], the general conclusion from a number of studies in RRS is that TDF treatment decreases BMD with stronger associations being seen in children and adolescents than in adults [64,150–152]. Thus, BMD may be more affected during the active period of bone growth and development. Among HIV-infected adolescents living in RLS, additional highly prevalent factors, including protein and energy malnutrition, micronutrient deficiencies, and childhood infections that are known to adversely affect bone mass accrual may pose additional threats to bone acquisition. To date, there are currently no published data in RLS where over 90% of infected adolescents live. This has inadvertently lead to lack of prevention and clinical management guidelines for this unique age group who may be at considerable risk of bone complications during a critical period of PBM attainment and subsequent lifelong ART exposure.

Constraints to diagnosis and management of bone loss in resource-limited settings

In 2015, 11 out of the 16 million people receiving ART globally were in the WHO Africa region alone [153]. However, unlike RRS where medications such as EFV are no longer preferred, and alternatives to TDF with less bone toxicity are likely to be more frequently used, there are currently no strategies in RLS for minimizing bone loss among HIV-infected individuals. The already limited funding, poor healthcare infrastructures, and sparse personnel pose tremendous challenges toward prevention and management of metabolic bone complications in RLS. As the standard assessment tool for BMD, DXA has only limited value as a single assessment. Serial assessments during HIV patient monitoring while on ART provide more information on the pattern of BMD changes [154]. In RLS, use of DXA scans in assessing BMD is limited by availability, cost, and training. In addition, once the diagnosis is obtained, the current cost of treatment medications for osteoporosis, for example, bisphosphonates is prohibitive. Furthermore, most healthcare personnel in most RLS lack the expertise to make appropriate diagnoses and provide relevant care.

Research needs

With more people starting ART [153] and living longer with HIV than ever before, more individuals will continue to experience osteoporosis and its sequelae, including fragility fractures [155]. Given low clinical and research capacity for metabolic bone disease in RLS, there is urgent special need for building capacity in bone healthcare and research. Expanding knowledge about bone health in RLS will not only provide significant insights into the burden of HIV-related bone loss in RLS but also predictors, and evolution of bone metabolic comorbidities in the time course of HIV infection and its lifelong treatment. An initial focus is needed to establish the epidemiology of metabolic bone diseases in both the general and HIV populations. We recommend prioritization of the following research agenda in RLS:

1. Cost-effective and feasible strategies to prevent osteoporosis for both HIV-infected and non-infected populations.
2. Identification of simple-low cost tools to detect early osteopenia.
3. Strategies to minimize or avoid ARV-associated bone loss such as ART choice, dose optimization, and ARV switching.
4. Research among HIV-infected populations focusing on women of reproductive age and special populations such as perinatally infected children and adolescents.

To successfully conduct research addressing the above mentioned gaps in bone health comorbidities in RLS, there is need to work through several existing research networks either regionally or globally. This will ensure effective design and quality implementation approaches are employed. Importantly, involving key policy makers both domestically and regionally upfront will make the future policy implementation more successful.

CONCLUSION

The review reveals overlapping prevalence of low BMD in RLS and RRS, with a generally higher prevalence of low BMD in RLS overall compared to RRS. We highlight important gaps in our knowledge about HIV-associated bone health comorbidities in RLS. In particular, there are scarce data on bone health mainly from cross-sectional studies that call for urgent need for research that can inform management guidelines in metabolic bone complications in RLS.

Acknowledgements

F.K.M. would like to thank Professors Todd T Brown and Mary Glenn Fowler, Dr Francis Kiweewa, MU-JHU Research Collaboration, Consortium for Advanced
Bone complications in HIV

Research and Training in Africa, Makerere University School of Public Health and University of the Witwatersrand.

Financial support and sponsorship
F.K.M. has received an R01 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number RO1AI18332NIH for bone health-related work as the Principal Investigator, and support as a site investigator on NIH-funded microbiome trials network protocols. K.R. has received support from Senior Research Scholar, Thailand Research Fund (TRF) for his work.

Conflicts of interest
There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as of special interest and of outstanding interest

1. The World Bank. World Bank list of economies. 2015. http://data.worldbank.org/about/country-classifications/country-and-lending-groups. [Accessed 8 December 2015]
2. UNAIDS. Report on the global AIDS epidemic 2013.
3. http://www.who.int/hiv/pub/guidelines/en/2013/13 Consolodiated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Accessed November 2015. Geneva, World Health Organization 2013.
4. Brown TT, Gaiqish RB. Antiretroviral therapy and the prevalence of osteoporosis: a meta-analytic review. AIDS 2006; 20:2165–2174.
5. Guerri-Fernández R, Vestergaard P, Carbonell C, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 2013; 28:1259–1263.
6. Piret-Alhambra D, Guerri-Fernandez R, De Vries F, et al. HIV infection and its association with an excess risk of clinical fractures: a nationwide case–control study. J Acquir Immune Defic Syndr 2014; 66:90–95.
7. A case–control study using data from the Danish National Health Service registries which show that HIV infection is associated with an almost three-fold increase in fracture risk compared with that of age and sex-matched uninfected patients. 27:1949.
8. A systematic review and meta-analysis which shows that HIV infection is associated with a modest increase in incident fracture. 21.
9. Battalora LA, Young B, Overton ET. Bones, fractures, antiretroviral therapy and HIV. Curr Infect Dis Rep 2014; 16:1–6.
10. Compton J. Osteoporosis and fracture risk associated with HIV infection and treatment. Endocrinol Metab Clin North Am 2014; 43:769–780.
11. Burge R, Dawson-Hughes B, Solomon D H, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007; 22:465–475.
12. Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci 2013; 68:1243–1251.
13. Morin S, Lix LM, Azmae M, et al. Mortality rates after incident nontraumatic fractures in older men and women. Osteoporos Int 2011; 22:2439–2448.
14. Jochwill O, Karis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004; 15:897–902.
15. Karis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137–1141.
16. Marshall D, Jochwill O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 313:1201–1208.
17. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:1165–1172.
18. Arntzen JJ, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42:1014–1020.
19. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42:1018–114.
20. McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41:1662–1670.
21. Mody K, Yarasheshki K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482–490.
22. Mody K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36 (Suppl 2):S101–S105.
23. Bonjour M, Fausto A, Crocetti P, et al. Nonimmunodeficiency virus side-effects of antiretrovirals: adverse effects and osteoporosis in HIV-infected subjects. J Antimicrob Chemother 2006; 58:485–486.
24. Brown TT. HIV: an unrecognized secondary cause of osteoporosis? J Bone Miner Res 2013; 28:1256–1258.
25. Yin MT, Overton ET. Increasing clarity on bone loss associated with antiretroviral initiation. J Infect Dis 2011; 203:1705–1707.
26. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937–946.
27. Nete LFP, Ragui-Eis V, Vieira Nilo FR, et al. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitom 2011; 14:434–439.
28. Módo R, Frazer EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015; 162:335–344.
29. Wunder DM, Bersinger NA, Fux CA, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007; 12:261.
30. Weitz T, Chilts K, Ibrahim F, et al. Elavizenzyme is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923–1928.
31. Retchel P, Croccora C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31:1240–1244.
32. Guadalupe-Grau A, Fuentes T, Guerra B, Calbet JA. Exercise and bone mass in adults. Sports Med 2009; 39:439–468.
33. Michelson D, Straktis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med 1996; 335:1176–1181.
34. Schwerz U, Deuschke M, Korner A, et al. Lumbar bone mineral density in patients with major depression. Am J Psychiatry 1994; 151:1691–1693.
35. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and testosterone-related toxicity. Best Pract Res Clin Endocrinol Metab 2011; 25:501–515.
36. Hernandez-Vailejo SJ, Beaupiere C, Larghero J, et al. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell 2013; 12:955–965.
37. Vukulina T, Fan X, Yamaguchi M, et al. Alterations in the immune-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 2010; 107:13848–13853.
38. Tangji K, Yunnava, A, Sheth E, B cell dysregulation promotes HIV-induced bone loss. In Journal of Bone and Mineral Research. 2013. Wiley-Blackwell 111 River St, Hoboken 07030–5774, NJ USA.
39. Ofotokun I, Tangji K, Vukulina T, et al. Role of T cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 2015; 6:8828.
40. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012; 205 (Suppl 3):S391–S399.
41. Bolland MJ, Grey A, Home AM, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol 2013; 76:643–648.
42. Navarro MC, Sosa M, Saavedra P, et al. Poverty is a risk factor for osteoporotic fractures. Osteoporos Int 2009; 20:393–398.
43. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827–2833.
44. Kim HS, Chin BS, Shin H-S. Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine. J Korean Med Sci 2013; 28:827–832.
45. Wundera, B., Agnes, K., Fred, S. et al. Low bone mineral density among Ugandan HIV-infected patients on failing first-line antiretroviral therapy: a sub-study of the EARNEST trial. 21st Conference on Retroviruses and Opportunistic Infections Boston, MA March 3-6, 2014. In Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. 2007. This is one of only a few studies which investigated the prevalence of osteoporosis among HIV-infected persons in sub-Saharan Africa.
46. Ofotokun I, Kulkarni M, Borak A, Dhand S. Prevalence of low bone mineral density among HIV patients on long-term suppressive antiretroviral therapy in resource limited setting of western India. J Int AIDS Soc 2014; 17:19567.
Bone health and HIV in resource-limited settings Matovu et al.

47. Alonge T, Okoje-Adesomoju V, Atalabi O, et al. Prevalence of abnormal bone mineral density in HIV-positive patients in Ibadan, Nigeria. J West Air Coll Surg 2013; 3:1–14.

48. The largest cross-sectional study in a cohort of HIV-infected adults in low and low-middle-income countries revealing a high prevalence of low bone mineral density.

49. Mayesni S, Utama S, Somaia A, et al. Factors influencing bone mineral density in ARV-naive patients at Sangrah Hospital, Bali. Acta Med Indones 2010; 45:175–179.

50. Alyn OA, Karasamangolu HK, Karasahinoglu R, et al. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis 2013; 17:707–711.

51. Zang L, Su Y, Hsieh E, et al. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy—A prospective observational study. BMC Musculoskelet Disord 2013; 14:224.

52. Wang Q, Liu J, Ding H, et al. Reduced bone mineral density among ART-naive male patients with HIV in China. Future Virol 2015; 10:827–833.

53. Shahar E, Segal E, Rozen GS, et al. Vitamin D status in young HIV infected women of different ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density. Clin Nutr 2013; 32:83–87.

54. Wattanacharunya L, Jantrapakde J, Avhingsanaw A, et al. Bone Mineral Density and Vitamin D Status in Antiretroviral-naive HIV-infected Thai: A Preliminary Result from a Five-Year Prospective Cohort Study. American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, George R. Brown Convention Center, September 13–15, 2014.

55. Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard care. AIDS. London, England 2013; 27:1243–1249.

56. Battalora L, Buchash K, Armon C, et al. Low bone mineral density and risk of incident fracture in HIV-infected adults. Antivir Ther 2015. [Epub ahead of print].

57. The first study demonstrating that low BMD was associated with incident fracture in HIV populations.

58. Short C-E, Shaw S, Fisher MJ, et al. Prevalence of and risk factors for osteopenia and fracture among a male HIV-infected population in the UK. Int J STD AIDS 2014; 25:113–121.

59. Mazzotta E, Ursini T, Agostinone A, et al. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: specificity and specificity ofcurrent guidelines on bone mineral density management. AIDS Patient Care STDS 2015; 29:169–180.

60. Kooij KW, Wit FW, Bischoff PH, et al. Low bone mineral density in patients with well suppressed HIV infection is largely explained by body weight, smoking and prior advanced HIV disease. J Infect Dis 2014; 211:539–548.

61. Kini E, Nishijima T, Mutohama D, et al. Long-term use of protease inhibitors is associated with bone mineral density loss. AIDS Res Hum Retroviruses 2014; 30:553–559.

62. Ovenden ET, Chisholm Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 2015; 162:815–824.

63. Cotteret S, Coia E, Simelane S, et al. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 2014; 28:2061–2060.

64. Carr A, Coia E, Neuhaus J, et al. International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1):137–146.

65. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191–201.

66. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. J Infect Dis 2008; 198:1591–1601.

67. Stellbrink HJ, Orkin C, Anrjas J, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSET study. Clin Infect Dis 2010; 51:963–972.

68. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir. Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791–1801.

69. Bernardini A, Moocott A, Mallon PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS1543 randomised trial. Lancet HIV 2015; 2:e464–e473.

70. Assoumou L, Katlama C, Viard JP, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS 2013; 27:2425–2430.

71. Taoio B, Chan ES, Fichtenbaum CJ, et al. Less bone loss with maraviroc compared to tenofovir-containing antiretroviral therapy in the ACTG A5303 study. Clin Infect Dis 2015; 61:1179–1188.

72. Brown TT, Ross AC, Storer N, et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus nonnucleoside regimens. Antivir Ther 2011; 16:1063–1072.

73. Ray D, Treger M, Sibilia J, et al. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-infected patients not on HAART. Clin Infect Dis 2015; 47:88–95.

74. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554–561.

75. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008; 13:1077–1082.

76. Kohler JJ, Hossein SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009; 89:513–519.

77. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi’s syndrome in HIV-infected patients: report of three cases and literature review. J Bone Miner Res 2004; 19:714–721.

78. Parsonsone MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6:341–346.

79. Williams J, Chadwick DR. Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia. J Infect Dis 2006; 52:e107–e108.

80. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273–1281.

81. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2005; 29:689–696.

82. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482–487.

83. Perrot S, Aslangul E, Gagliardini R, et al. Bone mineral density improvement after 48 weeks of switch to maraviroc – darunavir/ritonavir 300/800/100 mg OD, preliminary results of GUSTA study. J Int AIDS Soc 2014; 17 (Suppl 3): 199816.

84. Battalora L, Buchash K, Armon C, et al. Low bone mineral density and risk of incident fracture in HIV-infected adults. Antivir Ther 2015. [Epub ahead of print].
150. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582–584.

151. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116:e846–e854.

152. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711–e718.

153. Global health sector response to HIV, 2000–2015: focus on innovations in Africa: progress report. World Health Organization 2015. Accessed 8 December 2015. Available from: http://hesp-news.org/2015/12/06/global-health-sectorresponse-to-hiv-2000-2015-focus-on-innovations-in-africa/.

154. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes 2015; 22:446–451.

155. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect Dis 2015; 61:1850–1861.